Nxera Pharma partners with Antiverse to design GPCR-targeted antibody therapeutics using generative AI.
Read more
SUPLEXA shows promise in retraining immune cells for advanced Colorectal Neoplasms and Renal Cell Carcinoma.
Read more
HuidaGene's CRISPR/Cas13 RNA-editing therapy HG202 receives FDA clearance for Macular Degeneration treatment.
Read more
ALX Oncology to present Phase 1b/2 trial results of evorpacept and zanidatamab in HER2-positive Breast Neoplasms at SABCS 2024.
Read more
SimBioSys receives second FDA clearance for TumorSight Viz, enhancing breast cancer surgery decision support.
Read more
SUPLEXA shows promise in retraining immune cells for advanced Colorectal Neoplasms and Renal Cell Carcinoma.
Read more
Wave Life Sciences advances obesity and cardiometabolic RNA programs, with clinical trials set for 2025.
Read more
Eisai completes FDA submission for LEQEMBI subcutaneous dosing for early Alzheimer's Disease under Fast Track status.
Read more
Foghorn Therapeutics doses first patient in Phase 1 trial for SMARCA4 mutated NSCLC with FHD-909.
Read more
IDEAYA Biosciences advances darovasertib trials and reports strong financials, targeting multiple Phase 1/2 expansions in 2024.
Read more
Syndax and Royalty Pharma secure $350M funding for Niktimvo, targeting chronic Graft-versus-Host Disease.
Read more
OmniActive acquires ENovate Biolife to enhance its portfolio of clinically proven health ingredients.
Read more
Damona Pharmaceuticals receives FDA clearance for Phase 1 trial of DPX-101 targeting cognitive deficits in Major Depressive Disorder.
Read more
RIBOMIC's Phase IIa trial shows umedaptanib pegol increases growth rate in Achondroplasia by up to 4.6 cm/year in children.
Read more
Teva's Phase 3 SOLARIS trial shows TEV-'749 improves social functioning in Schizophrenia without PDSS events.
Read more
Ring Therapeutics partners with A*STAR and SERI to advance gene therapy R&D in Singapore for Ophthalmology and Oncology.
Read more
Illumina reports Q3 2024 revenue of $1.1 billion, lowers annual revenue guidance by 3%.
Read more
Formosa Pharmaceuticals' APP13007 shows success in Phase 3 trial for post-cataract surgery inflammation and pain in China.
Read more
Biotia's AI-powered urine test receives NY State approval for diagnosing Urinary Tract Infections with high accuracy.
Read more
J INTS BIO launches AI alliance to enhance precision medicine in Lung Neoplasms treatment.
Read more
PHAXIAM Therapeutics receives FDA approval for Phase II study on phage therapy for Prosthetic Joint Infections.
Read more
Xpert Mpox receives WHO Emergency Use Listing for rapid Mpox diagnosis.
Read more
AI in pathology market projected to reach USD 169.8 million by 2029, driven by digital pathology advancements.
Read more
Diadem's p53-specific antibody shows promise for early Alzheimer's Disease detection at CTAD 2024.
Read more
Leal Therapeutics secures $45M to advance ALS and Schizophrenia therapies to clinical trials by 2025.
Read more
